Dot1L-IN-1 (TFA)

Dot1L-IN-1 (TFA)

• UNSPSC Description: Dot1L-IN-1 TFA is a highly potent and selective Dot1L inhibitor with a Ki of 2 pM and an IC50 of 50=3 nM), as well as the activity of the HoxA9 promoter (IC50=17 nM) in HeLa and Molm-13 cells, respectively[1].
• Target Antigen: Histone Methyltransferase
• Type: Reference compound
• Related Pathways: Epigenetics
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/dot1l-in-1-tfa.html
• Purity: 98.56
• Solubility: DMSO : 50 mg/mL (ultrasonic)
• Smiles: CC1=NC=CC=C1C2=C(Cl)SC3=CC=C(NC(NCC(NCCCN(C)[C@@H]4CCCN(C5=C(C=CN6)C6=NC=N5)C4)=O)=O)C=C32.OC(C(F)(F)F)=O
• Molecular Weight: 760.23
• References & Citations: [1]Möbitz H, et al. Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach. ACS Med Chem Lett. 2017 Feb 14;8(3):338-343.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported